Evaluation of LBL-019 Monotherapy or Combined With Anti-PD-1 Antibody in the Treatment of Advanced Malignant Tumors
Clinical trial NCT05223231 · COMPLETED
Trial details
- NCT number
- NCT05223231
- Sponsor
- Nanjing Leads Biolabs Co.,Ltd
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-04-19
- Primary completion
- 2024-08-09
- Enrollment
- 26
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.